US 12,384,770 B2
Heterocyclic compound
Masahiro Ito, Kanagawa (JP); Hideyuki Sugiyama, Kanagawa (JP); Takeshi Yamamoto, Kanagawa (JP); Keiko Kakegawa, Kanagawa (JP); Jinxing Li, Kanagawa (JP); Junsi Wang, Kanagawa (JP); Takahito Kasahara, Kanagawa (JP); and Masato Yoshikawa, Kanagawa (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Apr. 15, 2024, as Appl. No. 18/635,839.
Application 18/635,839 is a division of application No. 17/952,546, filed on Sep. 26, 2022, granted, now 11,958,845.
Application 17/952,546 is a division of application No. 17/030,504, filed on Sep. 24, 2020, granted, now 11,453,661.
Claims priority of application No. 2019-177815 (JP), filed on Sep. 27, 2019.
Prior Publication US 2024/0343721 A1, Oct. 17, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 413/14 (2006.01); A61P 25/28 (2006.01); C07D 413/10 (2006.01)
CPC C07D 413/14 (2013.01) [A61P 25/28 (2018.01); C07D 413/10 (2013.01)] 5 Claims
 
1. A compound represented by the formula (I):

OG Complex Work Unit Chemistry
wherein
R1 is
(1) a C3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms,
(2) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a cyano group, and (iii) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and (iii) a C1-6 alkoxy group, or
(4) a 3- to 8-membered monocyclic non-aromatic heterocyclic group, and
R2 is
(1) a C3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms,
(2) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, and (ii) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom, (ii) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and (iii) a C1-6 alkoxy group, or
(4) a 3- to 8-membered monocyclic non-aromatic heterocyclic group,
or a salt thereof.